Exploring causes and consequences of early discontinuation of durvalumab after chemoradiotherapy for non-small cell lung cancer

Exploring causes and consequences of early discontinuation of durvalumab after chemoradiotherapy for non-small cell lung cancer

Introduction: For most locally advanced non–small cell lung cancer (LA-NSCLC) patients who complete definitive chemoradiotherapy (CRT) and do not experience disease progression, one year of adjuvant durvalumab is recommended. Here, we explore causes and consequences of early durvalumab discontinuati...

Descripció completa

Dades bibliogràfiques
Autors principals: Michael Pennock, Balazs Halmos, William Bodner, Haiying Cheng, Rasim Gucalp, Nitin Ohri
Format: Article
Idioma:English
Publicat: Elsevier 2023-07-01
Col·lecció:Clinical and Translational Radiation Oncology
Matèries:
Lung cancer
Immunotherapy
Radiotherapy
Durvalumab
Toxicity
Prognosis
Accés en línia:http://www.sciencedirect.com/science/article/pii/S240563082300068X

Internet

http://www.sciencedirect.com/science/article/pii/S240563082300068X

Ítems similars